Published in Pharma Investments, Ventures and Law Weekly, October 1st, 2006
According to a study from Japan, "Combined GC and combined GV are active and well tolerated chemotherapeutic regimens for patients with advanced NSCLC. The authors conducted a randomized Phase II study of GC versus GV to compare them in terms of efficacy and toxicity."
"One hundred twenty-eight patients with Stage IIIB or IV NSCLC were randomized to receive either carboplatin at an area under the curve of 5 on Day 1 combined with gemcitabine 1000 mg/m2 on Days 1 and 8...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly